Israel’s Omnix Medical (see here previously) has completed Phase 1 trials of its lead antimicrobial, nature-derived, peptide OMN6 on 80 patients to show its safety. It is now starting Phase 2 FDA-approved clinical trials to establish its efficacy, especially on superbugs.
https://www.clinicaltrialsarena.com/news/omnix-medical-approval-anti-infective-trial/